Randomized Evaluation of Patients With Stable Angina Comparing Diagnostic Examinations (RESCUE)
Primary Purpose
Chest Pain, Stable Angina Pectoris, CCS Class I to III, Angina Equivalent
Status
Terminated
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
CCTA
SPECT MPI/ICA
Sponsored by
About this trial
This is an interventional diagnostic trial for Chest Pain focused on measuring stable angina, recurrent chest pain, chest pain, angina equivalent, diagnosis, coronary artery disease
Eligibility Criteria
Inclusion Criteria:
- Willing and able to provide a written informed consent;
- 40 years or older;
- Presentation with symptoms of stable angina (CCS Class I to III) or angina equivalent with or without known CAD;
- Planned non-invasive imaging for CAD diagnosis;
- Able to tolerate CCTA or SPECT MPI per randomization as required by protocol, to be performed at an ACRIN-qualified facility with a RESCUE-qualified scanner.
Exclusion Criteria:
- Prior revascularization;
Not suitable to undergo CT with an iodinated contrast agent:
- Known allergy-like reaction to contrast media as defined by the American College of Radiology (ACR) (see www.acr.org/SecondaryMainMenuCategories/quality_safety/contrast_manual.aspx for reaction definition) or moderate to severe allergic reactions to more than one allergen;
- Renal failure, as determined by glomerular filtration rate (GFR) < 30 mL/min/1.73 m2 based on a serum creatinine level obtained within 28 days prior to registration;
- Renal insufficiency at the time of enrollment, as determined by GFR 30 to 60 mL/min/1.73 m2 based on a serum creatinine level obtained within 28 days prior to registration, unless permitted by the institution's policy and/or ACR guidance for risk reduction strategies (see www.acr.org/SecondaryMainMenuCategories/quality_safety/contrast_manual.aspx for guidance on contrast selection and pre-treatment strategies);
- Atrial fibrillation or significant arrhythmia judged to potentially limit quality of CCTA;
- Acute ischemia;
- Acute myocardial infarction;
- Severe myocardial ischemia: known markedly positive exercise treadmill stress test (significant ST segment depressions or hypotensive response during stage I of the Bruce protocol);
- Unable to suspend respiration for 15 seconds or to follow instructions to do so;
- Unstable angina and symptoms refractory to maximal oral and intravenous medical therapy (persistent CCS Class IV);
- History of known left ventricular ejection fraction < 45%;
- Pulmonary edema or heart failure unresponsive to standard medical therapy;
- Pacemaker;
- Valvular heart disease likely to require surgery in the next 18 months;
- Congenital heart disease or cardiomyopathy likely to affect prognosis during follow up;
- Significant systemic hypertension (blood pressure > 200/100 mm Hg) unresponsive to medical therapy;
- Severe noncardiovascular comorbidity limiting survival (e.g., cancer or other life threatening illness for which the patient is expected to live less than 12 months);
- Prior imaging evaluation for this episode of symptoms (e.g., SPECT MPI or CCTA within the previous 72 hours);
- BMI > 40 kg/m2;
- Pregnancy or intent to become pregnant (if a female is of childbearing potential-defined as a premenopausal female capable of becoming pregnant-a pregnancy test should be done prior to enrollment).
Sites / Locations
- Atlantic VA Medical Center
- Henry Ford Hospital
- Salem VA Medical Center
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Group A: CCTA Diagnostic
Group B: SPECT MPI/ICA Diagnostic
Arm Description
Participants randomized to diagnostic evaluation using CCTA to determine therapeutic course of action.
Standard-of-care diagnostic assessment using SPECT MPI, possibly followed by diagnostic ICA dependent on SPECT MPI results.
Outcomes
Primary Outcome Measures
Outcomes Comparison Between Group A and Group B Diagnostic Tests
To compare outcomes of participants with symptoms of stable angina or angina equivalent evaluated with an anatomic imaging strategy using CCTA as initial method of CAD diagnosis (Group A) to a combined functional and anatomic imaging strategy of SPECT MPI/ICA (Group B) as a guide to OMT alone.
Secondary Outcome Measures
Evaluate Prognostic Indices to Predict Outcomes
To evaluate the ability of available prognostic indices to predict revascularization or MACE using CCTA information and to develop new indices using the RESCUE trial data.
Cost, Effectiveness, and Incremental Cost-Effectiveness
To determine the cost, effectiveness, and incremental cost-effectiveness of CCTA versus SPECT MPI/ICA in the evaluation of participants with symptoms of stable angina.
Outcomes Related to Symptoms and Self-Reported Health Status
To compare angina symptoms and self-reported health status of participants with symptoms of stable angina undergoing CCTA as initial method of CAD diagnosis to SPECT MPI/ICA as a guide to OMT.
Full Information
NCT ID
NCT01262625
First Posted
December 15, 2010
Last Updated
June 11, 2018
Sponsor
American College of Radiology Imaging Network
1. Study Identification
Unique Protocol Identification Number
NCT01262625
Brief Title
Randomized Evaluation of Patients With Stable Angina Comparing Diagnostic Examinations
Acronym
RESCUE
Official Title
ACRIN 4701 RESCUE: Randomized Evaluation of Patients With Stable Angina Comparing Utilization of Diagnostic Examinations
Study Type
Interventional
2. Study Status
Record Verification Date
June 2018
Overall Recruitment Status
Terminated
Why Stopped
Funding timeline completed
Study Start Date
January 2011 (undefined)
Primary Completion Date
September 2014 (Actual)
Study Completion Date
September 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
American College of Radiology Imaging Network
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This randomized, controlled, diagnostic, multicenter trial will compare two diagnostic imaging pathways--coronary computed tomography angiography (CCTA) and single photon emission tomography (SPECT) myocardial perfusion imaging (MPI)--to determine the incidence of major adverse coronary events (MACE), defined as myocardial infarction (MI) or cardiac-related death, and cross-over to revascularization. CCTA may be used to direct patients with symptoms of stable angina or angina equivalent to optimal medical therapy (OMT). The use of CCTA as a diagnostic tool for angina symptoms will be associated with no increase in MACE or revascularization, decreased cost, reduced risks (e.g., less radiation exposure), additional insights into alternate explanations of chest pain, and increased cost-effectiveness in comparison with use of SPECT MPI/invasive coronary angiography (ICA).
Detailed Description
The Randomized Evaluation of Patients with Stable Angina Comparing Utilization of Diagnostic Examinations (RESCUE) is a multi-center randomized, controlled trial responding to the need for comparative analysis of these imaging technologies and the role of OMT in clinical care. A total of 4300 patients will be randomized to CCTA or SPECT MPI/ICA for diagnostic assessment of angina at up to 80 institutions internationally. This study builds on the results of the COURAGE trial by comparing CCTA and SPECT MPI/ICA integrated into a care paradigm featuring initial treatment with OMT for patients diagnosed with CAD without significant disease in the left main coronary artery. Participants will be followed for a composite endpoint of MACE and cross-over to revascularization over a follow-up period up to two years (two to six time points depending on diagnostic results and time of enrollment into the trial). The primary endpoint of the study is a combined endpoint of occurrence of MACE and revascularization. We will calculate differences in the combined MACE/revascularization endpoint between the CCTA and SPECT MPI/ICA arms. Participant outcomes will be assessed by age, gender, comorbidity, and angina classification class at presentation. Several comparative-effectiveness analyses will be performed. We hypothesize that the CCTA arm will be associated with no increase in MACE or revascularization, decreased cost, reduced risks (e.g., less radiation exposure), additional insights into or alternate explanations of chest pain, and increased cost-effectiveness in comparison with SPECT MPI/ICA. Findings are expected to result in validation of an evolving new standard of care for patients with stable angina that takes advantage of CCTA and OMT to more cost-effectively drive appropriate care while reducing the need for invasive diagnosis and increased radiation exposure with SPECT MPI/ICA.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chest Pain, Stable Angina Pectoris, CCS Class I to III, Angina Equivalent, Coronary Artery Disease
Keywords
stable angina, recurrent chest pain, chest pain, angina equivalent, diagnosis, coronary artery disease
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
1050 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Group A: CCTA Diagnostic
Arm Type
Experimental
Arm Description
Participants randomized to diagnostic evaluation using CCTA to determine therapeutic course of action.
Arm Title
Group B: SPECT MPI/ICA Diagnostic
Arm Type
Active Comparator
Arm Description
Standard-of-care diagnostic assessment using SPECT MPI, possibly followed by diagnostic ICA dependent on SPECT MPI results.
Intervention Type
Device
Intervention Name(s)
CCTA
Other Intervention Name(s)
coronary CT, cardiac CT
Intervention Description
Complete diagnostic CCTA per protocol specifications.
Intervention Type
Device
Intervention Name(s)
SPECT MPI/ICA
Other Intervention Name(s)
nuclear medicine cardiac stress test, stress test, nuclear medicine stress testc, cardiac stress test, exercise cardiac stress test, pharmacologic cardiac stress test
Intervention Description
Perform SPECT MPI per institutional standard practice; diagnostic ICA will be performed only as indicated per protocol.
Primary Outcome Measure Information:
Title
Outcomes Comparison Between Group A and Group B Diagnostic Tests
Description
To compare outcomes of participants with symptoms of stable angina or angina equivalent evaluated with an anatomic imaging strategy using CCTA as initial method of CAD diagnosis (Group A) to a combined functional and anatomic imaging strategy of SPECT MPI/ICA (Group B) as a guide to OMT alone.
Time Frame
up to 24 Months (depends on time of trial enrollment and funding duration)
Secondary Outcome Measure Information:
Title
Evaluate Prognostic Indices to Predict Outcomes
Description
To evaluate the ability of available prognostic indices to predict revascularization or MACE using CCTA information and to develop new indices using the RESCUE trial data.
Time Frame
24 Months
Title
Cost, Effectiveness, and Incremental Cost-Effectiveness
Description
To determine the cost, effectiveness, and incremental cost-effectiveness of CCTA versus SPECT MPI/ICA in the evaluation of participants with symptoms of stable angina.
Time Frame
6 and 12, and possibly 18 and 24 Months
Title
Outcomes Related to Symptoms and Self-Reported Health Status
Description
To compare angina symptoms and self-reported health status of participants with symptoms of stable angina undergoing CCTA as initial method of CAD diagnosis to SPECT MPI/ICA as a guide to OMT.
Time Frame
6 and 12, and possibly 18 and 24 Months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Willing and able to provide a written informed consent;
40 years or older;
Presentation with symptoms of stable angina (CCS Class I to III) or angina equivalent with or without known CAD;
Planned non-invasive imaging for CAD diagnosis;
Able to tolerate CCTA or SPECT MPI per randomization as required by protocol, to be performed at an ACRIN-qualified facility with a RESCUE-qualified scanner.
Exclusion Criteria:
Prior revascularization;
Not suitable to undergo CT with an iodinated contrast agent:
Known allergy-like reaction to contrast media as defined by the American College of Radiology (ACR) (see www.acr.org/SecondaryMainMenuCategories/quality_safety/contrast_manual.aspx for reaction definition) or moderate to severe allergic reactions to more than one allergen;
Renal failure, as determined by glomerular filtration rate (GFR) < 30 mL/min/1.73 m2 based on a serum creatinine level obtained within 28 days prior to registration;
Renal insufficiency at the time of enrollment, as determined by GFR 30 to 60 mL/min/1.73 m2 based on a serum creatinine level obtained within 28 days prior to registration, unless permitted by the institution's policy and/or ACR guidance for risk reduction strategies (see www.acr.org/SecondaryMainMenuCategories/quality_safety/contrast_manual.aspx for guidance on contrast selection and pre-treatment strategies);
Atrial fibrillation or significant arrhythmia judged to potentially limit quality of CCTA;
Acute ischemia;
Acute myocardial infarction;
Severe myocardial ischemia: known markedly positive exercise treadmill stress test (significant ST segment depressions or hypotensive response during stage I of the Bruce protocol);
Unable to suspend respiration for 15 seconds or to follow instructions to do so;
Unstable angina and symptoms refractory to maximal oral and intravenous medical therapy (persistent CCS Class IV);
History of known left ventricular ejection fraction < 45%;
Pulmonary edema or heart failure unresponsive to standard medical therapy;
Pacemaker;
Valvular heart disease likely to require surgery in the next 18 months;
Congenital heart disease or cardiomyopathy likely to affect prognosis during follow up;
Significant systemic hypertension (blood pressure > 200/100 mm Hg) unresponsive to medical therapy;
Severe noncardiovascular comorbidity limiting survival (e.g., cancer or other life threatening illness for which the patient is expected to live less than 12 months);
Prior imaging evaluation for this episode of symptoms (e.g., SPECT MPI or CCTA within the previous 72 hours);
BMI > 40 kg/m2;
Pregnancy or intent to become pregnant (if a female is of childbearing potential-defined as a premenopausal female capable of becoming pregnant-a pregnancy test should be done prior to enrollment).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Arthur Stillman, MD, PhD
Organizational Affiliation
Division of Cardiothoracic Imaging, Emory University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Pamela K Woodard, MD
Organizational Affiliation
Mallinckrodt Institute of Radiology, Washington University of Medicine
Official's Role
Study Chair
Facility Information:
Facility Name
Atlantic VA Medical Center
City
Decatur
State/Province
Georgia
ZIP/Postal Code
30033
Country
United States
Facility Name
Henry Ford Hospital
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48202
Country
United States
Facility Name
Salem VA Medical Center
City
Salem
State/Province
Virginia
ZIP/Postal Code
24153
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
17387127
Citation
Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, Casperson P, Harris CL, Chaitman BR, Shaw L, Gosselin G, Nawaz S, Title LM, Gau G, Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS, Mancini GB, Weintraub WS; COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007 Apr 12;356(15):1503-16. doi: 10.1056/NEJMoa070829. Epub 2007 Mar 26.
Results Reference
background
PubMed Identifier
18268144
Citation
Shaw LJ, Berman DS, Maron DJ, Mancini GB, Hayes SW, Hartigan PM, Weintraub WS, O'Rourke RA, Dada M, Spertus JA, Chaitman BR, Friedman J, Slomka P, Heller GV, Germano G, Gosselin G, Berger P, Kostuk WJ, Schwartz RG, Knudtson M, Veledar E, Bates ER, McCallister B, Teo KK, Boden WE; COURAGE Investigators. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation. 2008 Mar 11;117(10):1283-91. doi: 10.1161/CIRCULATIONAHA.107.743963. Epub 2008 Feb 11.
Results Reference
background
PubMed Identifier
33283579
Citation
Stillman AE, Gatsonis C, Lima JAC, Liu T, Snyder BS, Cormack J, Malholtra V, Schnall MD, Udelson JE, Hoffmann U, Woodard PK; RESCUE investigators *. Coronary Computed Tomography Angiography Compared With Single Photon Emission Computed Tomography Myocardial Perfusion Imaging as a Guide to Optimal Medical Therapy in Patients Presenting With Stable Angina: The RESCUE Trial. J Am Heart Assoc. 2020 Dec 15;9(24):e017993. doi: 10.1161/JAHA.120.017993. Epub 2020 Dec 5.
Results Reference
derived
Links:
URL
http://www.acrin.org/rescue_protocol.aspx
Description
Visit ACRIN.ORG for additional information, including trial protocol, contact information, recruitment materials, and other trial-related materials.
Learn more about this trial
Randomized Evaluation of Patients With Stable Angina Comparing Diagnostic Examinations
We'll reach out to this number within 24 hrs